Aberrant cytoplasmic expression of p63 and prostate cancer mortality

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 2, 2009, Pages 595-600

  Dhillon, Preet K ^a,b   Barry, Marc ^b   Stampfer, Meir J ^a   Perner, Sven ^b,c   Fiorentino, Michelangelo ^a   Fornari, Alessandro ^a   Jing, Ma ^a   Fleet, Julia ^a   Kurth, Tobias ^a   Rubin, Mark A ^b,c   Mucci, Lorelei A ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P63;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NICK END LABELING; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TISSUE MICROARRAY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; APOPTOSIS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; KI-67 ANTIGEN; MALE; MEMBRANE PROTEINS; MICROARRAY ANALYSIS; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 60549093217     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0785     Document Type: Article

References (42)

1. Trink B, Okami K, Wu L, Sriuranpong V, Jen J, Sidransky D. A new human p53 homologue. Nat Med 1998;4:747-8.
2. Signoretti S, Waltregny D, Dilks J, et al. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 2000;157:1769-75.
3. Marchini S, Marabese M, Marrazzo E, et al. ΔNp63 expression is associated with poor survival in ovarian cancer. Ann Oncol 2008;19:501-7.
4. Lo Muzio L, Santarelli A, Caltabiano R, et al. p63 overexpression associates with poor prognosis in head and neck squamous cell carcinoma. Hum Pathol 2005;36:187-94.
5. Zigeuner R, Tsybrovskyy O, Ratschek M, Rehak P, Lipsky K, Langner C. Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma. Urology 2004;63:1079-83.
6. Bismar TA, Demichelis F, Riva A, et al. Defining aggressive prostate cancer using a 12-gene model. Neoplasia 2006;8:59-68.
7. Mucci LA, Pawitan Y, Demichelis F, et al. Testing a multigene signature of prostate cancer death in the Swedish Watchful Waiting Cohort. Cancer Epidemiol Biomarkers Prev 2008;17:1682-8.
8. Narahashi T, Niki T, Wang T, et al. Cytoplasmic localization of p63 is associated with poor patient survival in lung adenocarcinoma. Histopathology 2006;49:349-57.
9. Hall MC, Womack S, Sagalowsky AI, Carmody T, Erickstad MD, Roehrborn CG. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology 1998;52:594-601.
10. Urist MJ, Di Como CJ, Lu ML, et al. Loss of p63 expression is associated with tumor progression in bladder cancer. Am J Pathol 2002;161:1199-206.
11. Yang A, Schweitzer R, Sun D, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999;398:714-8.
12. De Laurenzi V, Costanzo A, Barcaroli D, et al. Two new p73 splice variants, γ and δ, with different transcriptional activity. J Exp Med 1998;188:1763-8.
13. Flores ER. The roles of p63 in cancer. Cell Cycle 2007;6:300-4.
14. Keyes WM, Wu Y, Vogel H, Guo X, Lowe SW, Mills AA. p63 deficiency activates a program of cellular senescence and leads to accelerated aging. Genes Dev 2005;19:1986-99.
15. Li Y, Prives C. Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function? Oncogene 2007;26:2220-5.
16. Okamoto K, Prives C. A role of cyclin G in the process of apoptosis. Oncogene 1999;18:4606-15.
17. Yang A, Kaghad M, Wang Y, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998;2:305-16.
18. Di Como CJ, Urist MJ, Babayan I, et al. p63 expression profiles in human normal and tumor tissues. Clin Cancer Res 2002;8:494-501.
19. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 1989;321:129-35.
20. Christen WG, Gaziano JM, Hennekens CH. Design of Physicians' Health Study II-a randomized trial of β-carotene, vitamins E and C, multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials. Ann Epidemiol 2000;10:125-34.
21. Rubin MA, Bismar TA, Andren O, et al. Decreased α-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death. Cancer Epidemiol Biomarkers Prev 2005;14:1424-32.
22. Kim R, Demichelis F, Tang J, et al. Internet-based Profiler system as integrative framework to support translational research. BMC Bioinformatics 2005;6:304.
23. Molinie V, Herve JM, Lugagne PM, Lebret T, Botto H. Diagnostic utility of a p63/α-methyl coenzyme A racemase (p504s) cocktail in ambiguous lesions of the prostate upon needle biopsy. BJU Int 2006;97:1109-15.
24. Oliai BR, Kahane H, Epstein JI. Can basal cells be seen in adenocarcinoma of the prostate?: an immunohistochemical study using high molecular weight cytokeratin (clone 34βE12) antibody. Am J Surg Pathol 2002;26:1151-60.
25. Parsons JK, Gage WR, Nelson WG, De Marzo AM. p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis. Urology 2001;58:619-24.
26. Shah RB, Zhou M, LeBlanc M, Snyder M, Rubin MA. Comparison of the basal cell-specific markers, 34βE12 and p63, in the diagnosis of prostate cancer. Am J Surg Pathol 2002;26:1161-8.
27. Fabbro M, Henderson BR. Regulation of tumor suppressors by nuclear-cytoplasmic shuttling. Exp Cell Res 2003;282:59-69.
28. Hood JK, Silver PA. Diverse nuclear transport pathways regulate cell proliferation and oncogenesis. Biochim Biophys Acta 2000;1471:M31-41.
29. Rubin MA, Dunn R, Strawderman M, Pienta KJ. Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol 2002;26:312-9.
30. Osunkoya AO, Hansel DE, Sun X, Netto GJ, Epstein JI. Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: report of 21 cases. Am J Surg Pathol 2008;32:461-7.
31. Inoue T, Stuart J, Leno R, Maki CG. Nuclear import and export signals in control of the p53-related protein p73. J Biol Chem 2002;277:15053-60.
32. 1 checkpoint after DNA damage. Mol Cell Biol 1996;16:1126-37.
33. Moll UM, Riou G, Levine AJ. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci U S A 1992;89:7262-6.
34. Nie L, Sasaki M, Maki CG. Regulation of p53 nuclear export through sequential changes in conformation and ubiquitination. J Biol Chem 2007;282:14616-25.
35. Roth J, Dobbelstein M, Freedman DA, Shenk T, Levine AJ. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J 1998;17:554-64.
36. Tao W, Levine AJ. Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. Proc Natl Acad Sci U S A 1999;96:3077-80.
37. Bosari S, Viale G, Roncalli M, et al. p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcino-ma. Am J Pathol 1995;147:790-8.
38. Sun XF, Carstensen JM, Stal O, et al. Prognostic significance of p53 expression in relation to DNA ploidy in colorectal adenocarcinoma. Virchows Arch A Pathol Anat Histopathol 1993;423:443-8.
39. Geyer RK, Yu ZK, Maki CG. The MDM2 RING-finger domain is required to promote p53 nuclear export. Nat Cell Biol 2000;2:569-73.
40. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997;387:296-9.
41. Inoue T, Geyer RK, Howard D, Yu ZK, Maki CG. MDM2 can promote the ubiquitination, nuclear export, and degradation of p53 in the absence of direct binding. J Biol Chem 2001;276:45255-60.
42. Kadakia M, Slader C, Berberich SJ. Regulation of p63 function by Mdm2 and MdmX. DNA Cell Biol 2001;20:321-30.